Skip to main content

Soluble triggering receptor expressed on myeloid cells as a marker of non-infectious systemic inflammatory response syndrome


The objective was to determine the diagnostic significance of soluble triggering receptor expressed on myeloid cells (sTREM-1) as a marker of the systemic inflammatory response syndrome (SIRS) in ischemia/reperfusion (extracorporeal circulation).


Eighty-nine patients were included in the study. All patients were divided into: group 1 (n = 41) - coronary heart disease (CHD), group 2 (n = 47) - acquired heart diseases (AHD). All the operations were performed with normothermal nonpulsatile extracorporeal circulation (EC) with cold blood cardioplegia (coronary artery bypass surgery in the group with CHD and prosthetics/plastic valves for the group with AHD). Systemic inflammatory response (SIRS) was defined by Bone and colleagues [1]; ischemia and reperfusion by lactate and oxygen status of arterial and mixed venous blood (StatProfile). We studied by enzyme immunoassay level (ELISA): high-sensitivity C-reactive protein (hsCRP), procalcitonin (PCT-Q) and sTREM-1, using the sets by Bender Medsystems, CanAg and Brahms PCT-Q. Data are presented as mean ± standard deviation.


All patients registered the increased level of hsCRP, without significant difference between the two groups. At the point after the operation, the rate of hsCRP was significantly higher for the group AHD. Correlations were noted between levels of hsCRP and the frequency of occurrence of criteria for SIRS (r = 0.22 for the group of IHD, P = 0.03; r = 0.39 for the group AHD, P = 0.01). The odds ratio (OR) likelihood of SIRS complications on hsCRP was 2.4 in the group with CHD and 3.9 in the group with AHD. There was no significant difference between the rates of PCT for the corresponding points of comparison groups. The highest predictive value (OR = 2.9, P = 0.03) has a PCT in relation to the severity of SIRS in patients with AHD (infectious endocarditis and rheumatic heart disease). The sTREM-1 level was higher compared with the postoperative period (55.5 ± 8.8 vs. 77.8 ± 9.1 pg/ml, P = 0.005; 49.9 ± 6.7 vs. 87.5 ± 8.9 pg/ml, P = 0.004). We studied the correlation between the level of sTREM-1 and the frequency of occurrence of symptoms SIRS (r = 0.77 for the group of IHD, P = 0.002; r = 0.79 for the group AHD, P = 0.04). The OR sTREM-1 probability of SIRS complications was highest in comparison with all of the markers.


sTREM-1 has the greatest diagnostic significance in relation to non-infectious SIRS in ischemia/reperfusion.


  1. Bone RC, Balk RA, Cerra FB, et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655. 10.1378/chest.101.6.1644

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Grigoryev, E., Golovkin, A., Matveeva, V. et al. Soluble triggering receptor expressed on myeloid cells as a marker of non-infectious systemic inflammatory response syndrome. Crit Care 15 (Suppl 1), P420 (2011).

Download citation

  • Published:

  • DOI:


  • Coronary Heart Disease
  • Endocarditis
  • Systemic Inflammatory Response Syndrome
  • Myeloid Cell
  • Procalcitonin